Genentech Starts Building $750M Device Fill-Finish Expansion in Hillsboro
Genentech has broken ground on a $750 million device fill-finish expansion at its Hillsboro, Oregon site. The 211,000-square-foot addition will double the footprint of the existing facility, and commercial operations are targeted for 2031.
Our summary of an article from Plant Services. Read the original at Plant Services
What It Means
Device fill-finish is where biologics turn into products patients can actually use, and capacity there has become a real constraint. A five-year runway from groundbreaking to commercial operation shows how much of the schedule sits in equipment delivery, integration with an operating site, and commissioning, qualification and validation. Teams expanding a live GMP campus have to plan tie-ins and validation carefully so existing supply keeps running.
Read the original at Plant Services.
